National OncoVenture (NOV) is a Korean government funded oncology drug development program. We are focusing on non-clinical and early stage clinical development of promising oncology drug candidates. These candidates are provided by researchers in academics, research institutes, biotech and pharmaceutical companies. We are co-developing the compounds with the originators through a virtual development model. The majority of the development activities are outsourced to domestic and global CRO/CMOs as well as specialized laboratories throughout the world. During the pre-clinical and clinical development, we aim to improve the value of our candidates by out-licensing our development programs to global pharmaceutical companies who can develop them further for the global market.